The Vascular Birthmarks foundation, E.V.A. Clinic and Candela partner to provide pro-bono laser treatments

30 pre-qualified patients will receive treatment with the Vbeam Pulsed Dye Laser to commence the E.V.A. clinic’s-Vascular Birthmarks Foundation’s International Congress on Vascular Anomalies in Athens, Greece, June 7-8, 2019.

For the second year the Vascular Birthmark Foundation (VBF) organizes the International Congress on Vascular Anomalies in Europe. Candela Corporation, a leading global manufacturer of energy-based devices, will be partnering with the Vascular Birthmarks Foundation (VBF) and the European Vascular Anomalies clinic (E.V.A. clinic) to provide pro-bono Vbeam laser treatments to children and adults with birthmarks, port wine stains and other vascular related indications. The treatments will be performed at the E.V.A. clinic in Athens, Greece.

“We have many families that are looking to improve their child’s life with these treatments that help address vascular birthmarks. VBF has two primary referrals, Dr Stuart Nelson for the west coast and Dr. Geronemus for the east coast,” said Dr. Linda Rozell-Shannon, President & Founder of the Vascular Birthmarks Foundation. “There are specific parameters around using lasers on infants and children, and Dr Nelson and Dr. Geronemus not only follows the latest protocols available, but they have also seen the most clearance using the Vbeam laser system for these specific cases.”

The Vbeam Pulsed Dye Laser (PDL) is considered the gold-standard for the treatment of port wine stains and vascular anomalies in infants and children, as well as adults. Candela recently introduced the Vbeam Prima laser system to the market, representing the latest innovation in 30 years of clinical leadership for the Vbeam. “We are proud to sponsor incredible organizations, as VBF, whose work helps transform the lives of people every day. Their missions are inspirational and involve every year more and more doctors from all over the world. We are pleased that our devices can support those in need and offer outcomes that make a difference,” said Robert Fielitz, President & Managing Director Europe, Middle East & Africa Operations.

This conference, hosted in Athens by E.V.A clinic, in June 7-8 2019, is part of the Vascular Birthmarks Foundation international (iTEAM) outreach where expert physicians travel around the world to educate physicians regarding the latest in the diagnosis and treatment of vascular anomalies. At these conferences, free laser treatments are often offered to patients who have little access or cannot afford treatment. VBF is committed to every patient having fair and equal access to the latest treatment options for all vascular birthmarks, anomalies, tumors or syndromes.

The clinic’s Director and VBF-Europe Medical Co-Director Stavros Tombris MD, PhD, DDS, a Maxilo- Facial Surgeon with over 20 years of experience on Vascular Anomalies stated: “I am very proud that Candela, VBF and E.V.A. clinic were able to combine forces for the benefit of patients with Vascular Anomalies. We will always be aiming to provide advanced and highly specialized medical services to those affected by Vascular Lesions, as well as to promote research and further technological advances to enforce our vision.”

About Candela

Candela Corporation is a leading global medical aesthetic device company with an extensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical aesthetic applications including hair removal; wrinkle reduction; tattoo removal; women's health treatments; facial resurfacing; traumatic and surgical scar treatments; body contouring; improving the skin's appearance through the treatment of benign vascular and pigmented lesions; and the treatment of acne, leg veins, and cellulite. Candela has a wide portfolio of trusted, leading products, including the Vbeam®, Gentle® Family, CO2RE®, CO2RE Intima®, Exceed™, Nordlys™, Frax Pro™, Profound®, PicoWay®, and VelaShape®, as well as other energy-based platforms. Acquired by Apax Partners in July 2017, the Company markets, services and supports its products in over 100+ countries. It has offices in the United States, Australia, Canada, China, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Portugal, Spain and the United Kingdom, and many international distributors.

Vascular Birthmarks Foundation

The Vascular Birthmarks Foundation (VBF) is an international charitable organization that networks families affected by a vascular birthmark, tumor, or syndrome to the appropriate medical professionals for evaluation and/or treatment, provides informational resources as well as sponsors physician education, mobilizes medical missions trips, and supports research and programs that promote acceptance for individuals with birthmarks. VBF has networked over 125,000 children and adults into treatment since 1994. Established in 1994, by Founder and President, Linda Rozell-Shannon, PhD, VBF is the number one vascular birthmarks foundation in the world for patient education.

European Vascular Anomalies clinic

The European Vascular Anomalies clinic (E.V.A. clinic) is a modern medical unit providing specialized and coordinated services for patients with Hemangiomas and Vascular Malformations. Founded in 2017, it is an established medical facility for the treatment of Vascular Anomalies. The clinic’s physicians are highly trained Facial Surgeons, specialized in Maxillofacial, Plastic & Reconstructive Surgery, as well as Interventional Radiologists, Pathologists, Dermatologists and other related medical specialists. Located in Athens, Greece, it offers its services not only to local but to international patients as well. For more information about vascular birthmarks, tumors or anomalies and treatment options, please visit

For more information about Candela or the Vbeam Pulsed Dye Laser, please visit
Or contact: Maria Puca, Marketing Coordinator EMEA -

To Top

We use cookies on this site to enhance your user experience.

By continuing to browse you are agreeing to our use of cookies